Universidad de Chile
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 15, 2027The maintenance fee for Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ACE2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling (US 9,132,164) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others (US 11,795,476) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Curcumin-loaded nanoemulsions, method of manufacture, and method of preventive treatment using the same (US 11,813,355) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jun 24, 2027The maintenance fee for Method for genetic treatment using the AAV-XBP1s/GFP virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis (US 10,512,698) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,694,059 | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,050,920 | Biometric control method on the telephone network with speaker verification technology by using an intra speaker variability and additive noise unsupervised compensation In force · From the USPTO record | In force | From the USPTO record | |
| US 8,940,693 | Protein for the Immunocastration for Mammals In force · High confidence | In force | High confidence | |
| US 9,132,164 | Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ACE2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling In force · From the USPTO record | In force | From the USPTO record | |
| US PP29,727 | Nectarine tree named ‘Andes Nec-2’ In force · From the USPTO record | In force | From the USPTO record | |
| US PP25,893 | Nectarine tree named ‘Andes Nec-3’ In force · From the USPTO record | In force | From the USPTO record | |
| US 9,481,800 | Polymeric materials with antifouling, biocidal, antiviral and antimicrobial properties; elaboration method and its uses In force · From the USPTO record | In force | From the USPTO record | |
| US PP26,403 | Nectarine denominated ‘Andes Nec-1’ In force · From the USPTO record | In force | From the USPTO record | |
| US 10,274,677 | Control System and Procedure for Controlled Access by Means of an Optical Device Based on Flat Bands In force · High confidence | In force | High confidence | |
| US PP29,705 | Nectarine tree named ‘Andes Nec-4’ In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 33: 1 patent in force now held by others · 25 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 3 abandoned · 20 no status recorded